Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 1/20 | 0.64 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.64 |
| ▸ | POLB | P06746 | 1/20 | 0.61 |
| ▸ | FNTA | P49354 | 2/20 | 0.60 |
| ▸ | FNTB | P49356 | 2/20 | 0.60 |
| ▸ | HPGD | P15428 | 4/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.59 |
| ▸ | TSHR | P16473 | 2/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.59 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.59 |
| ▸ | LTA4H | P09960 | 1/20 | 0.59 |
| ▸ | GAA | P10253 | 1/20 | 0.59 |
| ▸ | GALR3 | O60755 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.56 |
| ▸ | MEN1 | O00255 | 2/20 | 0.56 |
| ▸ | MAPT | P10636 | 2/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.55 |
| ▸ | HTT | P42858 | 1/20 | 0.55 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.54 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14447211 | 1.00 | MTNR1A (0.64) | MTNR1AMTNR1BPOLBFNTAFNTB | |
| SCHEMBL14447213 | 0.90 | MTNR1A (0.54) | MTNR1AMTNR1BPOLBFNTAFNTB | |
| SCHEMBL2625088 | 0.89 | POLB (0.76) | POLBHPGDALDH1A1SMN1; SMN2GAA | |
| SCHEMBL14447210 | 0.87 | MTNR1B (0.66) | MTNR1AMTNR1BPOLBHPGDALDH1A1 | |
| SCHEMBL2173035 | 0.86 | MTNR1A (0.73) | MTNR1AMTNR1BPOLBHPGDALDH1A1 | |
| SCHEMBL2169725 | 0.86 | MTNR1A (0.78) | MTNR1AMTNR1BPOLBFNTAFNTB | |
| SCHEMBL11646606 | 0.85 | LTA4H (0.62) | POLBFNTAFNTBHPGDALDH1A1 | |
| SCHEMBL2170997 | 0.85 | MTNR1A (0.62) | MTNR1AMTNR1BPOLBFNTAFNTB | |
| SCHEMBL2171671 | 0.85 | L3MBTL1 (0.68) | MTNR1AMTNR1BFNTAFNTBHPGD | |
| SCHEMBL23323205 | 0.83 | POLB (0.68) | POLBFNTAFNTBHPGDALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120149706-A1 | INHIBITION OF P38 KINASE ACTIVITY USING SUBSTITUTED HETEROCYCLIC UREAS | DUMAS JACQUES (US) | 2012-06-14 | — | — | US | disclosed |
| US-20120149706-A1 | INHIBITION OF P38 KINASE ACTIVITY USING SUBSTITUTED HETEROCYCLIC UREAS | DUMAS JACQUES (US) | 2012-06-14 | — | — | US | disclosed |
| US-20120046290-A1 | INHIBITION OF P38 KINASE ACTIVITY USING SUBSTITUTED HETEROCYCLIC UREAS | BAYER HEALTHCARE LLC | 2012-02-23 | — | — | US | disclosed |
| US-20120046290-A1 | INHIBITION OF P38 KINASE ACTIVITY USING SUBSTITUTED HETEROCYCLIC UREAS | BAYER HEALTHCARE LLC | 2012-02-23 | — | — | US | disclosed |
| EP-2346821-A1 | SPHINGOSINE-1-PHOSPHATE RECEPTOR ANTAGONISTS | Exelixis, Inc. (US) | 2011-07-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149706-A1 | INHIBITION OF P38 KINASE ACTIVITY USING SUBSTITUTED HETEROCYCLIC UREAS | MAPK1, MAP3K1, MAP3K7 | MTNR1A 4231/4885MTNR1B 3950/4885POLB 2292/4885 |
| US-20120046290-A1 | INHIBITION OF P38 KINASE ACTIVITY USING SUBSTITUTED HETEROCYCLIC UREAS | MAPK1, MAP3K1, MAP3K7 | MTNR1A 4231/4885MTNR1B 3950/4885POLB 2292/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.